Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 2/20 | 0.37 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19032850 | 0.92 | GNAI3 (0.46) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL19629066 | 0.92 | GNAI3 (0.46) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL19032603 | 0.92 | GNAI3 (0.46) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL24113606 | 0.92 | GNAI3 (0.46) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL19040808 | 0.92 | GNAI3 (0.46) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL24701666 | 0.92 | GNAI3 (0.46) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL19032771 | 0.92 | GNAI3 (0.46) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL24113642 | 0.92 | GNAI3 (0.46) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL21115892 | 0.92 | GNAI3 (0.46) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL19032381 | 0.92 | GNAI3 (0.46) | L3MBTL1MEN1KMT2ATDP1GNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4522646-A2 | APOE LIPOPROTEIN SYSTEMS | Kisbee Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-4452928-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | Renagade Therapeutics Management Inc. (US) | 2024-10-30 | — | — | EP | disclosed |
| EP-4402121-A1 | ACYCLIC LIPIDS AND METHODS OF USE THEREOF | Renagade Therapeutics Management Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| EP-4402123-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | Renagade Therapeutics Management Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| WO-2023220387-A2 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023196931-A1 | CYCLIC LIPIDS AND LIPID NANOPARTICLES (LNP) FOR THE DELIVERY OF NUCLEIC ACIDS OR PEPTIDES FOR USE IN VACCINATING AGAINST INFECTIOUS AGENTS | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023122752-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20230202977-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2023044333-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-03-23 | — | — | WO | disclosed |
| WO-2023044343-A1 | ACYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202977-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | L3MBTL1 740/4885MEN1 2740/4885KMT2A 4436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.